Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function

Completed

Conditions studied: Use of Belatacept in Kidney Transplant Patients

In brief

Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus(BKV), Epstein-Barr Virus(EBV) and/or cytomegalovirus (CMV) infections.

Key facts

Study ID

NCT06091995

Run by

Methodist Health System

People needed

67

Starts

2022-08-22

Expected to finish

2025-07-07

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥18 years
• Received living or deceased donor kidney transplant during study period
• Documented DGF

You may not qualify if…

• Multiple organ transplant
• Recipients with acute rejection present on first biopsy evaluation before first belatacept dose
• Recipients with a first dose of belatacept after index discharge or tacrolimus initiation

Where it is running

• Methodist Dallas Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.